Search Results

This morning on the apheresis service, I saw a familiar face — one of our regular outpatients. He’s four weeks out from a total knee replacement and on baby aspirin twice a day. The nurse asked the inevitable question: “He’s anticoagulated…won’t he bleed if we do TPE?” It’s the instinctive worry. But the truth is more nuanced: anticoagulated  does not automatically mean high bleeding risk . Here’s how I think about it. 🔎How TPE and Anticoagulants Interact 1. Does TPE clear the drug? Heparin (UFH/LMWH):  cleared; anti-Xa activity drops across an exchange. DOACs:  variably removed; repeated procedures can lower levels significantly. Warfarin:  factor removal is the issue. Albumin replacement can raise INR by ~2 points — but that lab bump doesn’t automatically equal bleeding. 2. If so, should the dose be adjusted? Heparin:  often needs retitration  post-procedure. DOACs:  for infrequent outpatient TPE, dose after the run; for frequent or high-risk exchanges, consider anti-Xa checks or temporary heparin bridging. Warfarin:  no standardized pre-emptive adjustment; manage to clinical context, not just the transient INR spike. 3. How does circuit anticoagulation interact with systemic anticoagulation? TPE runs on citrate , which is normally metabolized quickly by the liver — so there’s no lingering systemic anticoagulation after the run. Exception:  in significant liver disease, citrate clearance is impaired. Combine that with systemic anticoagulants and the bleeding risk calculus gets trickier. 4. If bleeding starts, what can I reverse? Heparin → protamine Warfarin → PCC or vitamin K DOACs → idarucizumab (dabigatran) or andexanet (Xa inhibitors), if available Antiplatelets → no direct reversal; platelet transfusion if clinically indicated 5. What about antiplatelet agents? TPE doesn’t target platelets, but some are lost as collateral. Short courses:  usually low risk. Prolonged courses (>10 procedures):  bleeding risk rises when combined with anti-platelet agents. 🩸 Baseline hemostasis effects of TPE Albumin replacement  removes coag factors (esp. fibrinogen). Labs look “coagulopathic” post-exchange, but fibrinogen and factor VIII/vWF rebound within 24–48 h. Short courses:  bleeding is uncommon when calcium is managed and replacement chosen wisely. Long/intensive series + antiplatelets or liver disease:  bleeding risk is real and cumulative. 💡 Practical moves DOAC outpatient:  give the dose after TPE; monitor or bridge if procedures are frequent. Heparin inpatient:  expect anti-Xa to drop; plan a post-procedure check and adjust. Warfarin:  anticipate INR bump; don’t reflexively “correct” unless clinical bleeding or urgent hemostasis is needed. Antiplatelets:  not a contraindication; risk rises with longer TPE series. Outpatients with PIVs:  apply a firm pressure dressing  after removal. Even with “low-risk” anticoagulants, small venipuncture sites can ooze more than expected, and a pressure wrap reduces callbacks for bleeding. 🌟 Closing thought An anticoagulated patient on TPE does not  automatically equal bleeding. The real questions are: which drug, how often, what’s the replacement strategy, and what’s the patient’s baseline risk? For my patient today — aspirin, four weeks post-op — no intervention was needed. The art of apheresis is resisting reflexes, weighing real risks, and tailoring judgment to the person in front of you.

The other day, I asked an AI model about the Diego blood group system. It gave me a slick, confident answer — beautifully formatted, authoritative in tone — and completely wrong. If I were a patient, or even a busy clinician, I might not have caught it. But as a transfusion medicine physician, I knew immediately: this was a hallucination. And here’s the kicker — hallucinations like this aren’t just occasional glitches. They’re mathematically inevitable. The Myth of the Perfect AI Recent studies, including some from OpenAI itself, show that no matter how advanced large language models become, they will sometimes generate false information. That’s not because they’re “bad” or because engineers haven’t worked hard enough. It’s built into how they function. AI predicts the most likely next word, not the absolute truth. For common facts, it does pretty well. But for rare details — like unusual antigens, edge-case transfusion reactions, or cell therapy nuances — the statistical floor drops out. It’s harder to predict the next word for a rare scenario or very nuanced context. In these situations, the model is more likely to “make something up” than to leave a blank or express uncertainty. And in medicine, “making something up” isn’t just embarrassing. It’s dangerous. Why This Is Good News for Workers For those of us working in medicine, this is actually good news. Hallucinations prove that AI isn’t an autonomous replacement — it’s a sophisticated tool that still needs us. AI will be able to: Spot patterns in antibody panels faster than a human Suggest the most efficient inventory allocation Draft a transfusion reaction note in seconds But it will never guarantee accuracy in the cases that matter most. Rare antigens. Borderline transfusion decisions. Patients whose context changes the entire equation. Those are exactly the situations where hallucinations spike — and where human oversight is non-negotiable. As long as hallucinations exist, so does the need for human experts. For laboratorians and transfusion specialists, that’s not just job security — it’s reassurance that expertise remains indispensable. The Hybrid Future So what does the future of transfusion medicine look like in the AI era? I think of it as a “calculator moment.” AI will make our work faster, broader, and more efficient. It will handle the rote paperwork, surface the guidelines, and flag patterns across massive datasets that no human could scan in real time. But it won’t replace the expert at the bench or the physician making the final call. Instead, our role becomes even more vital: verifying, contextualizing, and deciding when the model is wrong. That’s not a bug in the system. That’s the point. Closing Thoughts When I asked the AI about Diego, it hallucinated. A transfusion medicine physician wouldn’t. That difference — the human check, the lived expertise — is what keeps medicine safe. AI hallucinations may be inevitable. But so is the ongoing need for human expertise in medicine. If anything, the rise of AI doesn’t erase our roles. It makes them stronger.

I’ve been out of training just long enough to start thinking about the long term. Over the years, I’ve sat through countless wellness talks and curricula, each with its own prescriptions: resilience workshops, mindfulness modules, burnout prevention checklists. Some were useful, many felt hollow. None fully captured what I’ve come to understand about how we sustain ourselves in medicine. So, I’ve started developing my own way of thinking — a kind of unified theory of wellness. The other night, I sat on the porch for the first time since moving here. The air was perfect — not too hot, not really chilly either. My husband and I watched people walk by, listened to the birds, and talked. Nothing urgent, nothing scheduled. Just being together. It felt like liquid time, the kind of moment where the clock drops away. Later I remembered there’s a Greek word for this: kairos . Unlike chronos  — the linear time of calendars and deadlines — kairos is time outside of time, the opportune moment, the kind of pause that feels like a gift. Inviting Kairos You can’t summon kairos the way you punch a clock. It doesn’t obey effort or demand. But you can  invite it. You can create spaces where it’s welcome — by slowing down, softening your pace, lingering a little longer. Kairos time can’t be commanded. It comes as grace — a quiet reminder that I am more than the clock that rules me. That evening on the porch was kairos. So is watching my cats in a sunspot, melted together in a beam of light. These moments can’t be forced, but when they arrive, they restore me. Curiosity as a Vital Sign If kairos is a gift, curiosity is the sign that I’m well enough to receive it. I’ve noticed that curiosity is the first thing to go when burnout creeps in  — the canary in the coal mine. When I’m exhausted or overextended, my questions dry up. I stop wanting to learn, explore, play. That’s why I think curiosity is one of the best metrics of mental health. It’s not only a measure of wellness, it’s also a practice that sustains wellness. To stay curious is to stay open to life. Mindfulness as Curious Endurance So where does mindfulness fit in? I think we often misunderstand it as sterile calmness, a blank mind. To me, mindfulness is much simpler: it’s the practice of remaining curious while uncomfortable . Restless in meditation? Be curious. Hungry, anxious, tired? Stay with it — not to fix it, but to see it. Mindfulness is a way of holding discomfort gently, asking questions instead of recoiling. It’s what makes room for kairos to slip in. Food as Spiritual Practice I also believe food is part of wellness in a way that’s both practical and spiritual. Eating isn’t just fuel; it’s memory, texture, community, story. When I accept food as spiritual, I eat with curiosity. I notice flavors, origins, the act of sharing. Meals, too, can open into kairos when approached with attention. A Theory of Wellness When I put all this together, I see a theory of wellness forming: Curiosity is the canary.  Its presence or absence tells me how I’m doing. Mindfulness is curious endurance.  It keeps me open even when life is uncomfortable. Kairos is the gift.  I can invite it but never command it. When it comes, it restores me. Food is spiritual.  Eating with curiosity connects me back to the world and to myself. Wellness, then, is not about perfection, or squeezing one more habit into the day. It’s about staying open enough to be curious, slowing down enough to invite kairos, and receiving those timeless gifts when they arrive. Closing On the porch that night, with birdsong and street sounds in the air, kairos found me. It always comes unannounced, and always feels like grace. My job is simply to make space, stay curious, and be ready to recognize the gift when it arrives. Curiosity is the path into kairos. And kairos is where curiosity learns to breathe.

In Part Two, we followed the fork in the road: cellular and tissue-based products that meet all four criteria in 21 CFR 1271.10(a) can stay in the lighter 361  pathway, while those that don’t become 351 biologics.  Now let’s zoom in fully on the 361 side — the “tissue world.” What Counts as a 361 Tissue? Classic 361 HCT/Ps  include: Tendons  → structural grafts used in orthopedic repair. Corneas  → restore vision by replacing a damaged cornea. Skin grafts  → cover burns or wounds. Bone grafts  → structural repair of skeletal defects. Amniotic membranes  → used as wound coverings. These are all minimally manipulated  and used for their original, homologous function  in the body. They’re not combined with active drugs or devices, and most are structural rather than systemic. That’s why they can remain in the 361 category. Reproductive Tissues: A Special Subset Reproductive tissues also fall under the 361 framework, but they’re worth highlighting separately because they are an explicit exception to the “systemic effect” rule. Examples : semen, oocytes, embryos, ovarian and testicular tissue. Why 361?  They are minimally manipulated (collected, frozen, thawed) and used for their homologous function — to enable reproduction. The carve-out:  Most HCT/Ps must not depend on systemic or metabolic activity to qualify as 361, but reproductive cells and tissues are the exception. Without this carve-out, assisted reproduction would require INDs and BLAs — an impossible barrier for routine fertility practice. Like other 361 tissues, reproductive HCT/Ps are regulated under 21 CFR 1271 Subparts A–D : donor screening/testing, registration, and good tissue practice. FDA also issues special guidance for communicable disease testing in this context. Why Minimal Manipulation + Homologous Use Matters These two criteria are the backbone of the 361 definition. Minimal manipulation  means the processing doesn’t alter the tissue’s relevant structural or biological characteristics. Freezing, shaping, or disinfecting = fine. Digesting into cells or culturing extensively = not minimal. Homologous use  means the product is used for the same basic function in the recipient that it served in the donor. Cornea → restores sight (same function). Bone → provides structural support (same function). Amnion → covers wounds (same barrier function). Sperm → fertilizes eggs (same function). Stay within those guardrails, and you remain a 361 product. Step outside, and you move into 351. When Tissues “Flip” Into 351 Territory Many products marketed as “stem cell” or “regenerative” therapies are actually tissues that don’t meet the 361 criteria . Amniotic membrane : If marketed simply as a wound covering = 361. If marketed as a source of stem cells with regenerative potential = 351. Bone grafts : Structural bone chips or paste = 361. Demineralized bone matrix marketed for its “inductive” properties to stimulate new bone growth = 351. Adipose tissue : Fat grafting for cushioning = 361. Isolating stromal vascular fraction for systemic regenerative claims = 351. The rule of thumb: once you claim systemic or metabolic effects—or manipulate the tissue beyond its natural form—you’ve crossed into biologics. Regulations That Apply 361 HCT/Ps are regulated under: PHS Act §361  → authority to prevent communicable disease transmission. 21 CFR 1271, Subparts A–D  → the tissue rules: Registration and listing of establishments Donor eligibility determination Screening/testing for communicable disease Current good tissue practice (cGTP): clean facilities, recordkeeping, labeling Notably, 361 products are not required to demonstrate clinical efficacy  before use. The regulatory framework is about safety from infection , not effectiveness . Contrast With Blood and 351 Cell Therapies This narrower focus sets 361 tissues apart from other regulated biologics: Blood : Regulated as both a drug and a biologic (FD&C Act + PHS Act), with requirements for manufacturing controls, labeling, and adverse event reporting in addition to donor testing. 351 Cell Therapies : Must prove safety, purity, and potency  through INDs, clinical trials, and BLAs. Every lot is produced under GMP and often requires product-specific release testing. 361 Tissues (including reproductive tissues) : Avoid the heavy biologics framework entirely, so long as they stay minimally manipulated and used homologously. Why It Matters The 361 pathway explains why corneas, tendons, semen, and skin grafts can be transplanted or used clinically every day without going through years of clinical trials. At the same time, it highlights why the FDA is cracking down on “stem cell clinics” that try to stretch 361 definitions beyond recognition. Understanding this distinction helps clarify not only what the law says , but also why some cellular therapies cost thousands and others cost hundreds of thousands.  The difference often comes down to which side of the 351/361 fork a product falls on. 📌 Wrapping Up the Series: Part One : Laws vs. regulations, FDA structure, and why blood is both a drug and a biologic. Part Two : The fork in the road — 351 vs. 361, and how FDA decides. Part Three : The 361 tissue world, including reproductive tissues, its boundaries, and its contrasts with blood and biologics. By untangling the alphabet soup, we can see the underlying logic: each pathway—blood, 351 cell therapies, 361 tissues—grew from the same legal roots but branched into different regulatory frameworks. And knowing those roots helps us understand where cellular therapy is headed next.

In Part One, we mapped out how laws and regulations interact, how the FDA is structured, and why blood is both a drug and a biologic. Now we turn to one of the most important dividing lines in cellular therapy regulation: the split between Section 351 and Section 361 of the Public Health Service (PHS) Act. This fork in the road determines how HCT/Ps (human cells, tissues, and cellular and tissue-based products) are regulated. Some are treated as 361 HCT/Ps  (tissues, regulated mainly for communicable disease control), while others are classified as 351 HCT/Ps  (biologics, requiring full FDA approval). It’s one of the first—and most consequential—questions to ask when thinking about any cellular product. The Four Criteria: 21 CFR 1271.10(a) FDA uses four criteria to decide if an HCT/P can remain a 361 product. To qualify, all four must be true : Minimal manipulation  — the tissue isn’t processed in a way that alters its original characteristics. Example : Cleaning, shaping, or cryopreserving a tendon = minimal. Digesting it into cells and reseeding a scaffold = more than minimal. Homologous use  — the product is used for the same function in the recipient as in the donor. Example : Cornea used to restore sight = homologous. Amniotic membrane marketed for “stem cell regenerative properties” = not homologous. Not combined with another active drug or device  — except for simple carriers or preservatives. No systemic effect / dependence on metabolic activity  — unless the use is autologous, in a first- or second-degree relative, or for reproductive use. This is the critical rule that separates many “tissues” from “biologics.” If a product fails even one of these, it is regulated as a 351 biologic. 361 HCT/P: The “Tissue” Path If all four criteria are met, the product stays under PHS Act 361  and 21 CFR 1271 (Subparts A–D) . Focus : communicable disease control, not clinical efficacy. Requirements : donor eligibility testing, good tissue practice (cGTP), registration and listing with FDA. Examples : tendons, corneas, skin grafts, bone fragments, semen. The Fourth Rule and Bone Marrow Transplants The “no systemic effect” rule is where confusion often arises. Most tissues—like tendons or corneas—are structural or local, so they qualify as 361. But what about hematopoietic stem cell (HSC) transplants ? Bone marrow, peripheral blood stem cells, and cord blood all have systemic effects  and depend on metabolic activity  to engraft and restore hematopoiesis. By the strict letter of the rule, they should be 351 biologics. FDA carves out an exception: if HSCs are for homologous use  (to reconstitute bone marrow), in an autologous setting , or between close relatives , they may remain under the 361 pathway. This is why routine bone marrow transplant programs operate under tissue-style regulation, not full BLAs. But once HSCs are expanded, manipulated, or gene-modified , they cross the line into 351. That’s why CAR-T cells  and ex vivo expanded HSCs  require more regulation. 351 HCT/P: The “Biologic” Path If you don’t meet all four criteria, you’re in PHS Act 351  territory. Regulation : under PHS 351, the FD&C Act, and Title 21 CFR (1271 + 210/211 + 600+). Burden : must demonstrate safety, purity, and potency to FDA’s satisfaction. Examples : CAR-T cells, most gene therapies, expanded stem cells. The Lifecycle of a 351 Product The development path is long, resource-intensive, and tightly monitored: Preclinical  — laboratory and animal studies show feasibility and basic safety. These are the foundation for first-in-human use. IND (Investigational New Drug application)  — filed with FDA before any patient receives the product. It includes preclinical data, detailed manufacturing protocols, and a proposed clinical trial plan. FDA reviews the IND mainly for patient safety . Clinical Trials Phase 1  → small numbers, focus on safety and dose-finding. Phase 2  → expands to measure efficacy signals while continuing safety monitoring. Phase 3  → large, often multicenter studies that provide definitive safety and efficacy data. BLA (Biologics License Application)  — the final submission. It must prove the product is safe, pure, and potent, and that the facility itself is GMP-compliant. FDA inspects the facility and reviews manufacturing controls as closely as it reviews clinical data. Post-market  — the responsibilities don’t stop at approval. Manufacturers must monitor for adverse events, report annually, and in some cases, conduct post-marketing studies. For CAR-T cells, each lot is tested and reviewed before release. This lifecycle explains why the cost and complexity of 351 products  is so much higher than 361. A tendon graft can move directly from a tissue bank to a surgeon. A CAR-T product must travel through a decade of trials and regulatory scrutiny before reaching a patient. Safety, Purity, and Potency: The Statutory Triad The PHS Act requires every biologic to be safe, pure, and potent.  For cellular products, those abstract words translate into specific assays: Safety Sterility testing (bacterial/fungal cultures) Mycoplasma PCR or culture Endotoxin (LAL assay) Replication-competent retrovirus (for gene-modified cells) Purity Flow cytometry (e.g., % CD3+ T cells in CAR-T products) Residual bead/cytokine/reagent testing Ensuring absence of contaminating cell types Potency Cytotoxicity assays (CAR-T killing tumor cells in vitro) Cytokine release assays (e.g., IFN-γ production) Colony-forming unit (CFU) assays for stem cells Differentiation assays for mesenchymal stromal cells These aren’t just lab tests—they’re the evidence that a product meets the PHS Act’s standard. They bridge the gap between statutory language and scientific reality. Why This Fork Matters The 351 vs. 361 split determines whether a product needs simple donor testing and tissue practice standards—or the full might of INDs, BLAs, and GMP inspections. It shapes the cost of therapies, the infrastructure required to deliver them, and the pace at which innovation reaches patients. Bone marrow, tendons, CAR-T cells—all fall somewhere on this spectrum. And the dividing line comes straight from the PHS Act, carried into practice through FDA’s regulations. 📌 Coming up in Part Three:  We’ll focus fully on the 361 world: tissues. What qualifies, what doesn’t, and how these products are regulated when they stay inside the 1271 box.

When I first dipped my toes into cellular therapy regulations, it felt like drowning in alphabet soup: PHS Act, FD&C Act, Title 21 CFR, CBER, CDER. Each acronym seemed to point in a different direction, and none of them came with a map. But beneath the jargon, there’s a simple framework: laws set the authority, regulations explain the rules, and FDA enforces both. Laws vs. Regulations: Who Does What? Laws  are written by Congress. They set the what : broad mandates about safety, efficacy, and public health. In our world, two laws matter most: The Public Health Service (PHS) Act  — governs biologics, including blood, tissues, and cellular therapies. It uses the famous triad: products must be safe, pure, and potent . The Federal Food, Drug, and Cosmetic (FD&C) Act  — governs drugs and devices, with a slightly different test: products must be safe and effective . Regulations  are written by FDA under the authority of those laws. They set the how . Regulations are published in the Code of Federal Regulations (CFR) , and for our field, it’s Title 21 (Food and Drugs) . 👉 Think of it this way: Congress says: “Biologics must be safe, pure, and potent.” FDA says: “Okay—here’s the rulebook for how you prove it: sterility testing, donor screening, validated potency assays, manufacturing standards.” The FDA’s Structure: Who Regulates What? FDA sits within the Department of Health and Human Services (HHS). Within FDA, there are centers —each with its own slice of responsibility. CBER (Center for Biologics Evaluation and Research)  → blood, cellular and gene therapies, tissues, vaccines, and related diagnostics. CDER (Center for Drug Evaluation and Research)  → drugs in the traditional sense: small molecules, monoclonal antibodies, most therapeutic proteins. That’s why CAR-T cell therapy  sits in CBER, while rituximab  (a monoclonal antibody) sits in CDER—even though both are used in hematology. This split confuses everyone at first, but it makes sense if you remember: CDER handles things that look like “chemicals in vials,” while CBER handles things that look like “cells, tissues, or blood.” Blood: The Perfect Example of Overlap Nothing illustrates the intersection of laws and regulations better than blood. Under the FD&C Act , blood is a drug . Under the PHS Act , blood is a biologic . That dual status means blood establishments must comply with a lattice of regulations : 21 CFR 210/211  — current good manufacturing practice (drugs). 21 CFR 600+  — general biologics requirements. 21 CFR 606  — blood establishment rules (donor eligibility, testing, quality systems). 21 CFR 640  — component-specific standards (RBCs, platelets, plasma, cryoprecipitate). If you’ve ever wondered why blood banking feels so heavily regulated, this is the reason: it’s both. Why Start Here? Because if you can understand how laws and regulations apply to blood—the most familiar cellular product—you’ll be better equipped to navigate the more complex world of stem cells, tissue grafts, and CAR-T therapies. Blood shows us three truths right away: Laws (PHS Act, FD&C Act) set the foundation. Regulations (21 CFR) provide the details. FDA (CBER/CDER) enforces both, often in overlapping ways. Once you see that pattern, the acronyms and numbers stop being noise. They start to form a map. 📌 Coming up in Part Two:  We’ll dig into the fork in the road between PHS 351 vs. 361 , how FDA decides if a product is a “biologic” versus a “tissue,” and what it actually takes for a 351 product to go from bench to bedside

Most of the time, our red cells are polite. They keep their surface antigens tucked away, only showing the parts of themselves that matter for ABO, Rh, and the usual cast of characters. But sometimes, hidden pieces of the red cell membrane — cryptantigens  — are suddenly exposed. When that happens, nearly every adult’s serum will react. The result is polyagglutination : the striking, messy agglutination of a patient’s red cells with most sera, even when ABO-compatible. It’s rare, it’s fascinating, and it can cause real confusion at the bench. Let’s walk through it. The Culprit: Cryptantigens Cryptantigens are usually masked by glycosylation or membrane structure. When they become exposed — through infection, clonal mutation, or inherited defects — they look like foreign antigens to the naturally occurring antibodies present in most adults. A key laboratory note: T family (T, Th, Tk, Tx)  antigens are recognized by Arachis hypogea (peanut) lectin . Tn antigen  is different — it is not recognized by peanut lectin , but is picked up by Helix pomatia (snail) lectin . Acquired Causes T Activation Mechanism:  Bacterial neuraminidase (from Clostridium perfringens , Streptococcus pneumoniae , and others) strips sialic acid from the red cell surface. Exposed antigens:  T, Th, Tk, Tx. Clinical associations:  Seen in sepsis, aHUS , and necrotizing enterocolitis . Key point:  This form is acquired and transient . Lab detection:  Arachis hypogea (peanut) lectin. Management:  Avoid plasma (full of anti-T antibodies), and if transfusion is necessary, use washed RBCs or platelets . Tn Polyagglutination Mechanism:  Acquired somatic mutation in a hematopoietic stem cell → defective glycosylation. Exposed antigen:  Tn antigen, distinct from the T family. Nature:   Acquired, clonal, persistent.  Sometimes shows mixed-field reactions. Lab detection:   Helix pomatia (snail) lectin , not peanut lectin. Associations:  May signal clonal hematopoiesis or preleukemic states. Inherited Causes HEMPAS (Congenital Dyserythropoietic Anemia II) Mechanism:  Inherited SEC23B mutation  → defective Golgi trafficking and incomplete glycosylation. Effect:  Cryptantigens are exposed and react with about one-third of adult sera . Clinical picture:  Chronic hemolytic anemia, multinucleated erythroblasts in marrow, positive acidified serum test. Hyde Park Polyagglutination Mechanism:  Inherited abnormal synthesis of Band 3  protein, described in individuals with Hemoglobin Hyde Park . Effect:  Membrane structural changes expose cryptantigens. Detection:  Confirmed with Sophora japonica lectin . Rarity:  Extremely uncommon, familial. Quick Reference Table Type Cause Exposed Antigen Nature Detection Notes T Activation Bacterial neuraminidase (infection) T, Th, Tk, Tx Acquired, transient Arachis hypogea (peanut) lectin Sepsis, aHUS, NEC; avoid plasma; wash RBCs/plt Tn Polyagglutination Somatic stem cell mutation Tn antigen Acquired, clonal Helix pomatia (snail) lectin Marrow disorders, preleukemia HEMPAS (CDA II) Inherited SEC23B  mutation Cryptantigens Inherited, persistent Acid serum test; ~1/3 sera positive Dyserythropoietic anemia Hyde Park Inherited abnormal Band 3 synthesis  (Hb Hyde Park) Cryptantigen Inherited, persistent Sophora japonica lectin Very rare familial condition Why It Matters Polyagglutination can be a diagnostic trap — suddenly, every crossmatch looks incompatible. Recognizing the pattern, reaching for lectins, and knowing which forms are acquired (T, Tn)  and which are inherited (HEMPAS, Hyde Park)  can help the blood banker avoid unnecessary delays, and in some cases, guide clinicians toward underlying conditions.

Most days in the blood bank, we’re juggling the usual suspects — ABO, Rh, Kell, Duffy, Kidd, MNS. But every now and then, an antibody pops up that doesn’t fit neatly into those boxes. That’s when the rare blood group systems come knocking: Diego, Cromer, Gerbich, and the rest of the “alphabet soup” that can send even seasoned transfusion medicine folks back to the reference books. These antigens don’t make headlines in every transfusion service, but when they do appear, they can mean the difference between finding compatible blood and delaying critical care. And the truth is — most of us don’t carry all these details in our heads. Why would we? They’re rare. But rare doesn’t mean unimportant. That’s why I put together a quick reference guide: something you can pull up on service, during board prep, or when you just need to remind yourself whether anti-Chido is clinically significant (spoiler: it’s not). What’s inside the guide Each system is broken down into: Antigens – high or low prevalence, defined where possible Genetics – the molecular basis (when known) Prevalence – who has it, and how often Antibody type – IgG vs IgM, reactivity patterns Clinical significance – HTRs, HDFN, or mostly nuisance Notes – testing pearls (like Sdᵃ being inhibited by guinea pig urine, or LWa being destroyed by DTT) I’ve included the systems that come up just enough to trip people up: Diego, Cromer, Gerbich, Chido/Rogers, Landsteiner–Wiener, Dombrock, Bennett–Goodspeed, Colton, Cartwright, Sid, and FORS. And for those who like to think ahead, there’s also a short overview of the 700 and 901 series (the collections and high-incidence buckets where tomorrow’s systems often begin). Why it matters For learners: Rare systems are high-yield board material, especially in transfusion medicine and immunohematology. For practice: Even if you never see anti-Wra in your blood bank career, you’ll eventually run into an antibody that doesn’t “fit” — and knowing how to interpret rarity vs significance is the key to safe transfusion. For curiosity: These systems are windows into red cell biology — from aquaporins to complement regulators to acetylcholinesterase. They remind us just how much the red cell carries beyond hemoglobin. Download the guide I’ve made the reference sheet available as a PDF download so you can keep it in your binder, your desktop, or your teaching slides: Final thought Blood group systems may be rare, but patients with rare antibodies are not imaginary. They show up in our hospitals, on our call nights, and in our transfusion reactions. Having a quick way to orient yourself can be the difference between feeling stuck and moving forward with confidence. This guide is my way of sharing a tool I wish I had earlier — compact, high-yield, and practical. I hope it helps you, your trainees, or your colleagues the next time an “uncommon and unforgettable” antibody shows up on your bench.

One of the challenges in transfusion medicine is that the most important areas of knowledge are not always the most glamorous. Beyond the intricacies of blood components, cellular therapies, and patient blood management, transfusion medicine professionals also need a solid foundation in statistics, quality systems, and regulatory frameworks. These topics often feel scattered — a little bit in textbooks, a little in regulatory documents, a little in accreditation checklists. They are also written in different languages: statistics speaks in sensitivity and specificity, regulations in acronyms and federal code, quality systems in cycles and root cause analyses. For learners, it can feel like stitching together three dialects just to follow one conversation. To help simplify this, I’ve created the Transfusion Medicine Quick Guides. These are concise, practical summaries designed to: Bring the key statistical concepts (sensitivity, specificity, PPV, NPV, likelihood ratios, Westgard rules, ROC curves, and how prevalence shapes predictive values) into one place. Clarify the major quality and regulatory frameworks, including the roles of CLIA, FDA, AABB, CAP, and FACT, as well as quality control vs quality assurance, process improvement tools, and hemovigilance. Provide a crosswalk of commonly confused terms, such as validation vs verification vs calibration, deviation vs deficiency, and error vs adverse event. These guides are written to be accessible whether you are: Preparing for transfusion medicine boards, Training residents, fellows, or laboratory staff, Or just refreshing your own memory before an inspection. 📄 Download the complete Transfusion Medicine Quick Guides (PDF) below: I hope this resource saves you time, provides clarity, and makes the less glamorous but deeply important side of transfusion medicine a little easier to navigate. 📌 Usage & Sharing This resource is free to use and share for educational purposes. Please credit Blood, Bytes, and Beyond  as the source if you distribute it or incorporate it into teaching materials.

When I first wrote my Fresh Frozen Facts  series, I focused on the workhorses. But plasma isn’t a single product: it’s a whole family, with cousins and spin-offs that have slightly different strengths, weaknesses, and roles. Today, let’s walk through the “plasma family tree” and see how FFP compares to PF24, thawed plasma, liquid plasma, cryopoor plasma, and solvent/detergent–treated plasma like Octaplas. 🧊 FFP (Fresh Frozen Plasma) Frozen within 8 hours of collection. Retains nearly all labile factors (especially V and VIII). Shelf life: 1 year at ≤ –18°C. Indications: the broad-spectrum plasma support we all know. ❌ Con: Requires freezer storage and thawing (30+ minutes), not “immediately available” in an emergency. ⏱️ PF24 (Plasma Frozen within 24 Hours) Frozen within 24 hours instead of 8. Reduced factor VIII, otherwise very similar to FFP. Shelf life: 1 year at ≤ –18°C. Often interchangeable with FFP in clinical practice. ❌ Con: That reduction in factor VIII may matter in certain bleeding disorders, though usually it is clinically insignificant. ❄️ Thawed Plasma FFP or PF24 that has been thawed and then stored at 1–6°C. Shelf life: up to 5 days after thawing. Factor V and VIII decline gradually, but most other factors remain stable. Role: stocked in some hospitals for faster turnaround in emergencies when FFP/PF24 would take too long to thaw. ❌ Con: Slightly reduced factor activity compared to freshly thawed FFP/PF24; short post-thaw shelf life. 💧 Liquid Plasma Collected and stored as plasma, never frozen. Stored at 1–6°C, shelf life up to 26–40 days (depending on regulatory body). Factor V and VIII decline during storage. Role: often stocked in trauma centers as “always ready” plasma for massive transfusion protocols (MTPs). ❌ Con: Lower levels of labile clotting factors make it less suitable for patients who need high VIII activity. 🩸 Cryopoor Plasma (CPP, Cryosupernatant) Plasma remaining after cryoprecipitate removal. Depleted in fibrinogen, factor VIII, and large vWF multimers. ADAMTS13 levels are normal, which is why CPP has been used as replacement fluid in TTP during therapeutic plasma exchange (TPE). Rarely used in the U.S. today, but still a recognized product. ❌ Con: Limited hemostatic utility outside TTP; largely obsolete for most other indications. 🧪 S/D Plasma (Solvent/Detergent–Treated Plasma) Plasma pooled from many donors, treated with solvent/detergent to inactivate lipid-enveloped viruses (HIV, HBV, HCV, etc.). Advantages: pathogen reduction, standardized factor levels, lower TRALI risk. Limitations: does not  inactivate non-enveloped viruses (HAV, parvovirus B19). Globally available under several names, but in the U.S. we use Octaplas. ❌ Con: Pooling introduces theoretical risk of donor-derived rare pathogens slipping through; supply and cost can also be limiting. 🌍 Octaplas (S/D Plasma, Octapharma) FDA-approved form of S/D plasma. Beyond solvent/detergent, Octaplas is passed through a PrP resin column to reduce abnormal prion proteins — a unique step not shared by all S/D plasmas worldwide. The clinical utility of this prion clearance step is unknown, but it is part of the FDA approval package. Indications: same as FFP, but often chosen for patients with multiple transfusion reactions or when pathogen-reduced products are preferred. Advantages: lower allergic reaction rates, consistency across units, potential added prion safety. ❌ Con: Expensive, availability may be limited compared to standard FFP/PF24, and not all institutions stock it. 🧾 Plasma Comparison Table Product Prep/Storage Factor Content Special Uses Pathogen/Prion Reduction Cons FFP Freeze ≤8h, –18°C, 1 yr Full (incl. labile factors) General plasma support Standard donor testing only Requires freezer/thaw time; not immediately available PF24 Freeze ≤24h, –18°C, 1 yr Slight ↓ VIII Interchangeable with FFP Standard donor testing only Slightly lower VIII levels Thawed Plasma Thawed FFP/PF24, 1–6°C, 5 d ↓ V, VIII over time Faster turnaround in emergencies Standard donor testing only Reduced factor activity; short post-thaw life Liquid Plasma Never frozen, 1–6°C, 26–40 d ↓ V, VIII over time “Always ready” for MTPs Standard donor testing only Declining clotting factor activity Cryopoor Plasma Post-cryoprecipitate Low fibrinogen, VIII, vWF multimers; normal ADAMTS13 TTP (replacement during TPE) Standard donor testing only Obsolete for most other uses S/D Plasma Pooled, solvent/detergent treated Standardized Broad use, ↓ TRALI risk Inactivates lipid-enveloped viruses only Doesn’t target non-enveloped viruses; cost Octaplas Pooled, solvent/detergent + PrP column Standardized Broad use, ↓ reactions Viral inactivation + PrP resin (prion clearance; clinical utility unknown) Higher cost; limited availability 🌟 Takeaway Plasma is not one-size-fits-all. FFP and PF24 dominate day-to-day use, but thawed plasma, liquid plasma, cryopoor plasma, and S/D products like Octaplas each have unique features and limitations. Knowing the differences — from “always ready” trauma plasma to prion-cleared Octaplas — helps match the right plasma to the right patient.

Mahesar A, et al. Platelet refractoriness during bone marrow transplantation: Comparison in aplastic anemia and beta thalassemia major patients. An experience of a public sector BMT unit in Pakistan. Biol Blood Marrow Transplant.  2020;26(3)(suppl):S210-S211. Introduction Platelet transfusion is a cornerstone of supportive care in hematology, oncology, and critical care. But what happens when patients fail to respond as expected? This phenomenon, known as platelet refractoriness , is defined as the failure to achieve the anticipated post-transfusion platelet count increment. Refractoriness matters because it is linked to an increased risk of bleeding, greater transfusion requirements, and significant challenges for both patient management and blood supply utilization. Measuring Refractoriness The most widely used tool for assessing platelet transfusion response is the Corrected Count Increment (CCI) . This metric adjusts the raw post-transfusion platelet count for patient size and the platelet dose received. CCI  = [(post-count – pre-count) × body surface area (m²)] ÷ number of platelets transfused (×10¹¹) Clinically, refractoriness is generally defined as a 1-hour CCI < 5,000–7,500 , though cutoffs may vary slightly between institutions. Causes of Platelet Refractoriness The causes of refractoriness fall broadly into non-immune  and immune  categories. Non-immune causes (most common): These account for the majority of cases and include fever, infection or sepsis, disseminated intravascular coagulation (DIC), splenomegaly, active bleeding, and certain medications. Because they are so common, they should always be considered first. Immune causes: When non-immune factors have been ruled out, immune mechanisms come into play. The most frequent is alloimmunization against human leukocyte antigens (HLA) . While the name suggests they only exist on leukocytes, HLA Class I antigens are also expressed on platelets. Less commonly, patients may develop antibodies against human platelet antigens (HPA) , typically seen in multiparous women or multiply transfused individuals. Evaluation A systematic evaluation helps distinguish between common, reversible factors and true alloimmune refractoriness. Step 1: Rule out non-immune contributors Review recent clinical events: fever, infection, sepsis, ongoing bleeding, or DIC. Assess splenomegaly via exam or imaging. Review medication list for drugs that impair platelet function or survival (e.g., amphotericin, vancomycin, certain antibiotics, heparin). Correct or stabilize these factors whenever possible. Many patients improve simply by addressing these issues. Step 2: Laboratory testing if refractoriness persists: If non-immune factors are unlikely or have been addressed, lab evaluation is the next step: HLA typing (donor and/or patient): Typing is typically performed at the DNA level (PCR-based molecular methods) to determine the patient’s HLA Class I antigens. This allows selection of compatible platelet donors. HLA antibody screen: Patient serum is tested against a panel of HLA antigens using solid-phase assays (e.g., bead-based methods on flow cytometry or Luminex platforms). This identifies alloantibodies and their specificities. Panel Reactive Antibody (PRA): PRA is a summary measure that estimates the percentage of the donor population against which the patient has HLA antibodies. A higher PRA indicates broader sensitization and fewer compatible donors. Platelet crossmatch: Patient serum is incubated with donor platelets to detect compatibility. This is usually performed by flow cytometry or solid-phase assays. Crossmatching has the advantage of providing a result within hours and can capture both HLA and HPA incompatibilities. HPA testing: In select cases where HPA alloimmunization is suspected (often multiparous women or heavily transfused patients), molecular typing of the patient and donor, along with antibody testing, can identify incompatibilities. HPA testing is less common but may explain rare refractory cases. This structured workflow ensures that patients are not prematurely labeled as “immune refractory,” avoiding unnecessary use of scarce matched products. Management Treatment depends on the underlying cause: Non-immune causes:  Addressing the underlying condition is paramount—controlling infection, managing DIC, stopping an offending drug, or stabilizing bleeding. Optimizing the patient’s overall clinical status often restores transfusion responsiveness. Immune causes: HLA-compatible platelets:  The most common first step. This involves selecting donor platelets that lack the specific HLA antigens against which the patient has antibodies. Often identified using antibody specificity prediction or virtual crossmatching. HLA-matched platelets:  Platelets selected from donors who share the patient’s HLA type. Sourcing typically relies on registry databases or directed donation. Crossmatched platelets:  A faster and more practical option than full HLA-matching, particularly useful when PRA is low or turnaround time is critical. Again, crossmatching will identify incompatibility with both HLA and HPA antigens. PRA-guided strategy:  A PRA ≥ 20%  indicates a significant alloimmunization burden, meaning random donor platelets are unlikely to be compatible. At this threshold, the additional expense and labor of selecting matched or compatible platelets is justified. HPA-matched platelets:  Reserved for rare, complex cases when HPA antibodies are confirmed. Adjunctive measures:  Antifibrinolytics and other supportive therapies may be used in bleeding patients while definitive therapy is arranged. Practical Challenges Even with the best plan, management is rarely straightforward. Donor availability is limited, testing and procurement take time, and resource constraints often force compromises between the ideal and the feasible. Clinicians must balance patient safety, transfusion stewardship, and logistical realities. Conclusion Platelet refractoriness is a complex and often multifactorial problem . The majority of cases are non-immune in origin, but immune causes—particularly HLA alloimmunization—pose significant challenges. A systematic approach that prioritizes ruling out common non-immune contributors, followed by targeted immune evaluation and thoughtful transfusion strategy, helps ensure that patients receive the safest and most effective care possible.

I’ve been taught a lot about resilience. It’s a buzzword now — built into wellness curricula, baked into institutional language, handed out like a balm for burnout. We’re offered resiliency toolkits and mindfulness apps, taught breathing exercises and positive reframing. The idea is that if we just regulate our emotions well enough, we can withstand anything. In theory, it’s empowering. In practice, it often feels hollow. Because real resilience — the kind forged in complex, unjust, high-pressure environments — looks nothing like a slide deck. It isn’t always calm. It isn’t always pretty. And it certainly isn’t a personal growth opportunity neatly disguised as institutional neglect. What no one tells you is that resilience sometimes looks like grief. Or anger. Or stubborn silence. It looks like being misunderstood and still showing up. It looks like refusing to disappear — even when invisibility would be safer. Resilience isn’t about bouncing back. It’s about remaining yourself when everything around you suggests you shouldn’t. The Tension in Mastering Our Fates Invictus By William Ernest Henley   Out of the night that covers me, Black as the Pit from pole to pole, I thank whatever gods may be For my unconquerable soul. In the fell clutch of circumstance I have not winced nor cried aloud. Under the bludgeonings of chance My head is bloody, but unbowed. Beyond this place of wrath and tears Looms but the Horror of the shade, And yet the menace of the years Finds, and shall find me, unafraid. It matters not how strait the gate, How charged with punishments the scroll, I am the master of my fate, I am the captain of my soul. Henley’s words are spare and defiant, clenched against the world. They speak of a soul that cannot be conquered, no matter the pain or the pressure. And yet, as much as I love this poem — and I do — I’ve also come to see its limits. Because we are not  the masters of our fate, not entirely. The scroll is charged with punishments we didn’t write. The gate is narrow for reasons we didn’t choose. Control is unevenly distributed, privilege unevenly granted. And still, Henley’s voice offers something that is true: when all else is taken, we still have ourselves. Our will. Our response. Our refusal to bow. Amanda Knox and the Interior Life That truth echoes in an essay by Amanda Knox, reflecting on her years in an Italian prison for a crime she did not commit. She describes the moment when she realized, fully and finally: This is still my life. Not the life she wanted, not the one she planned, but hers nonetheless. And within that stark, narrow space, she still had choices — how to spend her time, how to carry herself, how to stay human in a place designed to strip that away. That moment has stayed with me. Because her insight wasn’t grand or defiant — it was intimate. She didn’t rise with poetry. She simply claimed her own interior  in a place that sought to erase it. It made me realize that resilience isn’t always loud. It isn’t always visible. Sometimes it looks like survival inside a system designed to break you. Sometimes it’s choosing to live  in a life you didn’t ask for, with dignity, depth, and deliberate care. Maya Angelou and the Radiance of Refusal Still I Rise By Maya Angelou   You may write me down in history With your bitter, twisted lies, You may trod me in the very dirt But still, like dust, I'll rise.   Does my sassiness upset you? Why are you beset with gloom? ’Cause I walk like I've got oil wells Pumping in my living room.   Just like moons and like suns, With the certainty of tides, Just like hopes springing high, Still I'll rise.   Did you want to see me broken? Bowed head and lowered eyes? Shoulders falling down like teardrops, Weakened by my soulful cries?   Does my haughtiness offend you? Don't you take it awful hard ’Cause I laugh like I've got gold mines Diggin’ in my own backyard.   You may shoot me with your words, You may cut me with your eyes, You may kill me with your hatefulness, But still, like air, I’ll rise.   Does my sexiness upset you? Does it come as a surprise That I dance like I've got diamonds At the meeting of my thighs?   Out of the huts of history’s shame I rise Up from a past that’s rooted in pain I rise I'm a black ocean, leaping and wide, Welling and swelling I bear in the tide.   Leaving behind nights of terror and fear I rise Into a daybreak that’s wondrously clear I rise Bringing the gifts that my ancestors gave, I am the dream and the hope of the slave. I rise I rise I rise.   Where Henley grits his teeth and Knox reclaims her interior, Maya Angelou rises. Not just surviving — but refusing to be erased. Her resilience isn’t armored or stoic; it’s radiant, embodied, and unmistakably hers. She doesn’t shrink, doesn’t explain, doesn’t wait to be welcomed. She rises — again and again — like something inevitable. But rising like that doesn’t happen by accident. It takes effort to move with grace through a world that wants you flattened. It takes energy to meet erasure with joy — or even with composure. Angelou’s poem isn’t just a declaration. It’s a record of resistance, of showing up with presence and power when everything pushes you to vanish. And that’s what resiliency training never touches: Not just the courage it takes to keep going, but the labor of continuing. The Work of Resilience Resilience, as it’s often presented, sounds passive — like a quality you either possess or don’t. But the real thing takes labor. It takes waking up after another night of unrest and doing what needs to be done anyway. It takes managing perception, emotion, logistics, and reputation — often simultaneously. It takes discerning what to fight for and what to let go. It takes choosing, again and again, not to go numb. And even that’s not always enough. Because no one is resilient alone . There are privileges that make resilience possible: safety nets, mentors, second chances, being believed. There’s chance and timing and luck. There are people who see you when you’re breaking and quietly help hold the pieces together. Without those, survival can feel like a private, grinding miracle — the kind that looks effortless from the outside but costs everything on the inside. That’s what no one tells you. Resilience isn’t a glow-up. It’s a grind. And for most of those who live it, there’s no award, no parade — just the quiet, difficult work of continuing. What’s Left Out of the Slide Deck Resilience isn’t a personal virtue. It’s a practice. A labor. A negotiation between who you are and what the world demands of you. It’s not about bouncing back — it’s about carrying on in a life you didn’t ask for, in systems that weren't designed for you, with people who may never understand what it costs you to be there. Sometimes resilience looks like grace. Sometimes it looks like exhaustion. Sometimes it looks like a person who keeps showing up — not because it’s redemptive, but because it’s necessary. That’s the part we leave out: Not that resilience is rare, but that it is hard. And it’s still happening, quietly, in people all around you — whether you recognize it or not.